about
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Present and future of lung cancer vaccines.
@ast
Present and future of lung cancer vaccines.
@en
type
label
Present and future of lung cancer vaccines.
@ast
Present and future of lung cancer vaccines.
@en
prefLabel
Present and future of lung cancer vaccines.
@ast
Present and future of lung cancer vaccines.
@en
P2093
P2860
P1476
Present and future of lung cancer vaccines.
@en
P2093
Eckhard R Podack
Joseph D Rosenblatt
Luis E Raez
P2860
P304
P356
10.1517/14728214.11.3.445
P407
P577
2006-09-01T00:00:00Z